G
Giovanni Del Poeta
Researcher at University of Rome Tor Vergata
Publications - 233
Citations - 7577
Giovanni Del Poeta is an academic researcher from University of Rome Tor Vergata. The author has contributed to research in topics: Chronic lymphocytic leukemia & Leukemia. The author has an hindex of 38, co-authored 217 publications receiving 6769 citations. Previous affiliations of Giovanni Del Poeta include Catholic University of the Sacred Heart.
Papers
More filters
Journal ArticleDOI
Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia
Davide Rossi,Silvia Rasi,Valeria Spina,Alessio Bruscaggin,Sara Monti,Carmela Ciardullo,Clara Deambrogi,Hossein Khiabanian,Roberto Serra,Francesco Bertoni,Francesco Forconi,Francesco Forconi,Luca Laurenti,Roberto Marasca,Michele Dal-Bo,Francesca Rossi,Pietro Bulian,Josep F. Nomdedeu,Giovanni Del Poeta,Valter Gattei,Laura Pasqualucci,Laura Pasqualucci,Raul Rabadan,Robin Foà,Riccardo Dalla-Favera,Gianluca Gaidano +25 more
TL;DR: This integrated mutational and cytogenetic model independently predicted survival, improved CLL prognostication accuracy compared with FISH karyotype, and was externally validated in an independent CLL cohort.
Journal ArticleDOI
Analysis of regulatory T-cell changes in patients with idiopathic thrombocytopenic purpura receiving B cell–depleting therapy with rituximab
Roberto Stasi,Nichola Cooper,Giovanni Del Poeta,Elisa Stipa,Maria Laura Evangelista,Elisabetta Abruzzese,Sergio Amadori +6 more
TL;DR: Patients with active ITP have a defective T regulatory cell compartment that can be modulated by a B cell-targeted therapy, and patients, particularly responders, showed restored numbers of Tregs as well as a restored regulatory function upon treatment with rituximab.
Journal ArticleDOI
Amount of spontaneous apoptosis detected by Bax/Bcl-2 ratio predicts outcome in acute myeloid leukemia (AML)
Giovanni Del Poeta,Adriano Venditti,Maria Ilaria Del Principe,Luca Maurillo,Francesco Buccisano,Anna Tamburini,Maria Christina Cox,A. Franchi,Antonio Bruno,Carla Mazzone,Paola Panetta,G Suppo,Mario Masi,Sergio Amadori +13 more
TL;DR: In this paper, an index (bax/bcl-2) obtained by dividing bax mean fluorescence intensity (MFI) and bax-2 MFI was found to accurately predict the clinical response and outcome of patients with normal or unknown cytogenetics.
Journal ArticleDOI
Response to B-cell-depleting therapy with rituximab reverts the abnormalities of T-cell subsets in patients with idiopathic thrombocytopenic purpura
Roberto Stasi,Giovanni Del Poeta,Elisa Stipa,Maria Laura Evangelista,Margherita M. Trawinska,Nichola Cooper,Sergio Amadori +6 more
TL;DR: In patients with ITP, response to B-cell depletion induced by rituximab is associated with significant changes of the T-cell compartment, and abnormalities were reverted in responders at 3 and 6 months after treatment, whereas they remained unchanged in nonresponders.
Journal ArticleDOI
Prognostic and therapeutic implications of minimal residual disease detection in acute myeloid leukemia
Francesco Buccisano,Luca Maurillo,Maria Ilaria Del Principe,Giovanni Del Poeta,Giuseppe Sconocchia,Francesco Lo-Coco,William Arcese,Sergio Amadori,Adriano Venditti +8 more
TL;DR: Evidence supporting the appropriateness of incorporating MRD detection into the AML risk assessment process is examined and a comprehensive prognostic algorithm, generated by combining pretreatment cytogenetics/genetics and posttreatment MRD determination, is recommended.